Nothing Special   »   [go: up one dir, main page]

BR112018072953A2 - polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos - Google Patents

polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos

Info

Publication number
BR112018072953A2
BR112018072953A2 BR112018072953-1A BR112018072953A BR112018072953A2 BR 112018072953 A2 BR112018072953 A2 BR 112018072953A2 BR 112018072953 A BR112018072953 A BR 112018072953A BR 112018072953 A2 BR112018072953 A2 BR 112018072953A2
Authority
BR
Brazil
Prior art keywords
cd40l
methods
fusion polypeptides
fusion protein
antibody
Prior art date
Application number
BR112018072953-1A
Other languages
English (en)
Inventor
Baca Manuel
Drabic Stacey
Emtage Peter
Herbst Ronald
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Publication of BR112018072953A2 publication Critical patent/BR112018072953A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

é aqui proporcionada uma proteína de fusão de cd40l-fc e métodos de uso da proteína de fusão no tratamento de câncer compreendendo a administração da proteína de fusão de cd40l-fc ou proteína de fusão cd40l-fc em combinação com um ou mais inibidores de pontos de verificação imunes (por exemplo, um anticorpo anti-ctla4, anticorpo anti-pd-l1).
BR112018072953-1A 2016-05-13 2017-05-12 polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos BR112018072953A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662336129P 2016-05-13 2016-05-13
US62/336,129 2016-05-13
PCT/US2017/032352 WO2017197231A1 (en) 2016-05-13 2017-05-12 Cd40l-fc fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112018072953A2 true BR112018072953A2 (pt) 2019-02-19

Family

ID=60267851

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072953-1A BR112018072953A2 (pt) 2016-05-13 2017-05-12 polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos

Country Status (18)

Country Link
US (1) US10975155B2 (pt)
EP (1) EP3455263A4 (pt)
JP (1) JP2019523636A (pt)
KR (1) KR20190004319A (pt)
CN (1) CN109153729A (pt)
AR (1) AR108468A1 (pt)
AU (1) AU2017264944A1 (pt)
BR (1) BR112018072953A2 (pt)
CA (1) CA3022636A1 (pt)
CL (1) CL2018003141A1 (pt)
CO (1) CO2018013104A2 (pt)
IL (1) IL262727A (pt)
MA (1) MA44993A (pt)
MX (1) MX2018013762A (pt)
RU (1) RU2018138703A (pt)
SG (1) SG11201809374VA (pt)
TW (1) TW201741337A (pt)
WO (1) WO2017197231A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025236T2 (en) * 2008-07-21 2016-03-29 Apogenix Gmbh TNFSF single chain molecules
EP3043816B1 (en) 2013-09-11 2019-08-14 MedImmune Limited Anti-b7-h1 antibodies for treating tumors
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
CN112543773B (zh) 2018-07-11 2024-05-31 卡尔医学有限公司 SIRPα-4-1BBL变体融合蛋白及其使用方法
US20220135649A1 (en) * 2019-02-06 2022-05-05 The Regents Of The University Of California Dominant negative cd40l polypeptides
US20220259278A1 (en) * 2019-07-08 2022-08-18 Progen Co., Ltd. Novel fusion protein and use of same
TW202124440A (zh) * 2019-09-05 2021-07-01 瑞典商阿斯特捷利康公司 用於治療晚期肺癌之組成物及方法
JP2023512951A (ja) * 2020-01-23 2023-03-30 ジェネクシン・インコーポレイテッド Ｐｄ－ｌ１タンパク質が含まれた融合タンパク質およびその用途
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
WO2024208936A1 (en) 2023-04-05 2024-10-10 F. Hoffmann-La Roche Ag In vitro cultivation method for antibody expressing cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832229B1 (en) * 1995-06-07 2004-01-14 Immunex Corporation Cd40l mutein
CA2259962C (en) * 1996-07-08 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications of t-bam (cd40l) technology to treat diseases involving smooth muscle cells
US6774225B2 (en) 1999-04-15 2004-08-10 Hong Kong University Of Science & Technology Antigenized antibody vaccine for foot-and-mouth disease
ATE545703T1 (de) * 2000-07-25 2012-03-15 Immunomedics Inc Multivalentes zielbindendes protein
DE60227285D1 (de) * 2001-12-21 2008-08-07 Immunex Corp Rekombinante polypeptide
EP3243839A1 (en) * 2005-05-20 2017-11-15 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
HUE025236T2 (en) * 2008-07-21 2016-03-29 Apogenix Gmbh TNFSF single chain molecules
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
CA2984350A1 (en) * 2015-05-04 2016-11-10 Apogenix Ag Single-chain cd40-receptor agonist proteins

Also Published As

Publication number Publication date
CN109153729A (zh) 2019-01-04
CL2018003141A1 (es) 2018-12-28
WO2017197231A1 (en) 2017-11-16
JP2019523636A (ja) 2019-08-29
CO2018013104A2 (es) 2018-12-14
IL262727A (en) 2018-12-31
RU2018138703A (ru) 2020-06-15
TW201741337A (zh) 2017-12-01
MA44993A (fr) 2019-03-20
US10975155B2 (en) 2021-04-13
MX2018013762A (es) 2019-03-28
AU2017264944A1 (en) 2018-12-20
EP3455263A4 (en) 2020-01-01
AR108468A1 (es) 2018-08-22
KR20190004319A (ko) 2019-01-11
US20170327588A1 (en) 2017-11-16
SG11201809374VA (en) 2018-11-29
CA3022636A1 (en) 2017-11-16
EP3455263A1 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
BR112018072953A2 (pt) polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
MX2024005976A (es) Un anticuerpo anti-tigit, un anticuerpo anti-pvrig y un anticuerpo anti-pd-1 para usarse en el tratamiento de cancer.
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
CL2019000760A1 (es) Tratamiento de migraña refractaria
BR112019011186A2 (pt) conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
BR112018013914A2 (pt) polipeptídeos heterodiméricos condicionalmente ativos e métodos de utilização deste
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
CO2020010345A2 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
BR112019014986A8 (pt) Anticorpo que alveja bcma e uso do mesmo
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
PH12017500190A1 (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
BR112018002824A2 (pt) anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo
CR20170351A (es) Proteínas de unión a icos
MX2021010119A (es) Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1.
BR112018013094A2 (pt) combinação de inibidor de hdac e anticorpo de anti-pd-l1 para o tratamento de câncer ovariano
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
MX2021005377A (es) Terapias dirigidas a cdcp1.
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
BR112016029935A2 (pt) ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
BR112018072268A2 (pt) ensaio de potência relativa para vetor viral que codifica isomerohidrolases
BR112019011461A2 (pt) terapia celular à base de nk melhorada

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]